{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T17:26:57Z","timestamp":1787074017851,"version":"build-2736575974"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Liaoning Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024-BS-175"],"award-info":[{"award-number":["2024-BS-175"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070831"],"award-info":[{"award-number":["82070831"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300897"],"award-info":[{"award-number":["82300897"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbrc.2026.154330","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:31:11Z","timestamp":1784763071000},"page":"154330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The role of the LPC\/ATX\/LPA axis in metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1016","volume":"831","author":[{"given":"Yuwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4119-2585","authenticated-orcid":false,"given":"Lu","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154330_bib1","article-title":"Post-transplant MASLD: a risk-stratified approach to assessment and personalized management","volume":"13","author":"Huang","year":"2026","journal-title":"Front. Med."},{"key":"10.1016\/j.bbrc.2026.154330_bib2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/life16060915","article-title":"Advances in non-alcoholic fatty liver disease: pathophysiology, diagnosis, and emerging therapies","volume":"16","author":"Katsaros","year":"2026","journal-title":"Life"},{"key":"10.1016\/j.bbrc.2026.154330_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108593","article-title":"Berberine prevents NAFLD and HCC by modulating metabolic disorders","volume":"254","author":"Lin","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2026.154330_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2026-002294","article-title":"Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications","volume":"13","author":"Tachi","year":"2026","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.bbrc.2026.154330_bib5","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154330_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252312809","article-title":"Metabolomic hallmarks of obesity and metabolic dysfunction-associated steatotic liver disease","volume":"25","author":"Beyo\u011flu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154330_bib7","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/HEP.0000000000000786","article-title":"Molecular mechanisms in MASLD\/MASH-related HCC","volume":"82","author":"Wang","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2026.154330_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13395-025-00375-5","article-title":"Dysregulated ATX-LPA and YAP\/TAZ signaling in dystrophic Sgcd-\/- mice with early fibrosis and inflammation","volume":"15","author":"Guti\u00e9rrez-Rojas","year":"2025","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.bbrc.2026.154330_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117443","article-title":"The mechanisms of lysophosphatidylcholine in the development of diseases","volume":"247","author":"Liu","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2026.154330_bib10","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/ijms20051149","article-title":"An updated review of lysophosphatidylcholine metabolism in human diseases","volume":"20","author":"Law","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154330_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12916-016-0552-3","article-title":"Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study","volume":"14","author":"K\u00fchn","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.bbrc.2026.154330_bib12","first-page":"65","article-title":"Phosphatidylcholine: greasing the cholesterol transport machinery","volume":"8","author":"Lagace","year":"2015","journal-title":"Lipid Insights"},{"key":"10.1016\/j.bbrc.2026.154330_bib13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/ijms24021353","article-title":"The phospholipase A2 superfamily: structure, isozymes, catalysis, physiologic and pathologic roles","volume":"24","author":"Khan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154330_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119069","article-title":"Lysophosphatidylcholine as a mechanistic and therapeutic nexus in atherosclerotic cardiovascular disease","volume":"197","author":"Lai","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2026.154330_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/JCI171267","article-title":"Blood-derived lysophospholipid sustains hepatic phospholipids and fat storage necessary for hepatoprotection in overnutrition","volume":"133","author":"Chin","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2026.154330_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00011-012-0434-x","article-title":"Prevention of 1-palmitoyl lysophosphatidylcholine-induced inflammation by polyunsaturated acyl lysophosphatidylcholine","volume":"61","author":"Hung","year":"2012","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bbrc.2026.154330_bib17","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1074\/jbc.M116.721340","article-title":"Mfsd2a is a transporter for the essential \u03c9-3 fatty acid docosahexaenoic acid (DHA) in eye and is important for photoreceptor cell development","volume":"291","author":"Wong","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154330_bib18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nature13241","article-title":"Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid","volume":"509","author":"Nguyen","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154330_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s11658-021-00276-7","article-title":"Targeting the GPR119\/incretin axis: a promising new therapy for metabolic-associated fatty liver disease","volume":"26","author":"Zhao","year":"2021","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.bbrc.2026.154330_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.mce.2017.12.002","article-title":"Lysophosphatidylcholine and its phosphorothioate analogues potentiate insulin secretion via GPR40 (FFAR1), GPR55 and GPR119 receptors in a different manner","volume":"472","author":"Drzazga","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bbrc.2026.154330_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdnut.2023.101985","article-title":"Lysophosphatidylcholine-rich nutrition therapy increased gut absorption of coingested dietary fat: a randomized controlled trial","volume":"7","author":"Tindall","year":"2023","journal-title":"Curr. Dev. Nutr."},{"key":"10.1016\/j.bbrc.2026.154330_bib22","doi-asserted-by":"crossref","first-page":"11033","DOI":"10.1074\/jbc.RA118.002752","article-title":"Lysophospholipids induce innate immune transdifferentiation of endothelial cells, resulting in prolonged endothelial activation","volume":"293","author":"Li","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154330_bib23","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1113\/JP284262","article-title":"Modes of action of lysophospholipids as endogenous activators of the TRPV4 ion channel","volume":"601","author":"Ben\u00edtez-Angeles","year":"2023","journal-title":"J. Physiol."},{"key":"10.1016\/j.bbrc.2026.154330_bib24","first-page":"97","article-title":"Inhibitors of the autotaxin-lysophosphatidic acid axis and their potential in the treatment of interstitial lung disease: current perspectives","volume":"12","author":"Zulfikar","year":"2020","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.154330_bib25","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/S0021-9258(18)45911-X","article-title":"Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein","volume":"267","author":"Stracke","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154330_bib26","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.3390\/ijms25147737","article-title":"Autotaxin\u2013lysophosphatidate axis: promoter of cancer development and possible therapeutic implications","volume":"25","author":"Laface","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154330_bib27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3390\/cells10040939","article-title":"The expression regulation and biological function of autotaxin","volume":"10","author":"Zhang","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2026.154330_bib28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jcmgh.2022.07.012","article-title":"Hepatocyte-secreted autotaxin exacerbates nonalcoholic fatty liver disease through autocrine inhibition of the PPAR\u03b1\/FGF21 axis","volume":"14","author":"Qiu","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154330_bib29","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.3390\/cancers14215437","article-title":"Autotaxin in breast cancer: role, epigenetic regulation and clinical implications","volume":"14","author":"Drosouni","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2026.154330_bib30","doi-asserted-by":"crossref","first-page":"34654","DOI":"10.1074\/jbc.M111.276725","article-title":"Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells","volume":"286","author":"Fulkerson","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154330_bib31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fmed.2018.00180","article-title":"Autotaxin in pathophysiology and pulmonary fibrosis","volume":"5","author":"Ninou","year":"2018","journal-title":"Front. Med."},{"key":"10.1016\/j.bbrc.2026.154330_bib32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1096\/fj.13-232868","article-title":"Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration","volume":"28","author":"Wu","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.bbrc.2026.154330_bib33","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1194\/jlr.R046391","article-title":"Autotaxin: structure-function and signaling","volume":"55","author":"Perrakis","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbrc.2026.154330_bib34","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.3390\/ijms21197002","article-title":"Structure-based discovery of novel chemical classes of autotaxin inhibitors","volume":"21","author":"Magkrioti","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154330_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/wjon1762","article-title":"Autotaxin and lysophosphatidate signaling: prime targets for mitigating therapy resistance in breast cancer","volume":"15","author":"Benesch","year":"2024","journal-title":"World J. Oncol."},{"key":"10.1016\/j.bbrc.2026.154330_bib36","doi-asserted-by":"crossref","first-page":"G60","DOI":"10.1152\/ajpgi.00462.2025","article-title":"Macrophage-specific autotaxin deficiency promotes hepatic steatosis and inflammation in diet-induced MASLD","volume":"331","author":"Park","year":"2026","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbrc.2026.154330_bib37","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.3390\/ijms27062548","article-title":"Autotaxin and lysophosphatidic acid circulating levels correlate with body mass index in obese subjects with MASLD","volume":"27","author":"Tatoli","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154330_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/13543784.2024.2305126","article-title":"Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis","volume":"33","author":"Simonetti","year":"2024","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.bbrc.2026.154330_bib39","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1001\/jama.2023.5355","article-title":"ISABELA 1 and 2 investigators, Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials","volume":"329","author":"Maher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2026.154330_bib40","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000779","article-title":"Serum autotaxin levels predict liver-related events in patients with primary biliary cholangitis: a long-term multicenter observational study","volume":"15","author":"Iwadare","year":"2024","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.bbrc.2026.154330_bib41","article-title":"Autotaxin: a potential biomarker for primary biliary cholangitis","volume":"10","author":"Yang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrc.2026.154330_bib42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40560-021-00559-3","article-title":"Autotaxin levels in serum and bronchoalveolar lavage fluid are associated with inflammatory and fibrotic biomarkers and the clinical outcome in patients with acute respiratory distress syndrome","volume":"9","author":"Gao","year":"2021","journal-title":"J. Intensiv. Care"},{"key":"10.1016\/j.bbrc.2026.154330_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.922945","article-title":"Roles of autotaxin\/autotaxin-lysophosphatidic acid axis in the initiation and progression of liver cancer","volume":"12","author":"She","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154330_bib44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s43018-023-00703-y","article-title":"Autotaxin\u2013lysolipid signaling suppresses a CCL11\u2013eosinophil axis to promote pancreatic cancer progression","volume":"5","author":"Bhattacharyya","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.bbrc.2026.154330_bib45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbalip.2012.09.013","article-title":"Autotaxin in embryonic development","volume":"1831","author":"Moolenaar","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2026.154330_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108421","article-title":"Lysophosphatidic acid, a simple phospholipid with myriad functions","volume":"246","author":"Yanagida","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2026.154330_bib47","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.biochi.2010.04.015","article-title":"Biological roles of lysophosphatidic acid signaling through its production by autotaxin","volume":"92","author":"Okudaira","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.bbrc.2026.154330_bib48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/cancers12010105","article-title":"Autotaxin implication in cancer metastasis and autoimunne disorders: functional implication of binding autotaxin to the cell surface","volume":"12","author":"Peyruchaud","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2026.154330_bib49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fphys.2017.00153","article-title":"Lysophosphatidic acid pretreatment attenuates myocardial ischemia\/reperfusion injury in the immature hearts of rats","volume":"8","author":"Chen","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bbrc.2026.154330_bib50","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1080\/15548627.2022.2039000","article-title":"A defective lysophosphatidic acid-autophagy axis increases miscarriage risk by restricting decidual macrophage residence","volume":"18","author":"Yang","year":"2022","journal-title":"Autophagy"},{"key":"10.1016\/j.bbrc.2026.154330_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.917471","article-title":"Lysophosphatidic acid signaling and microRNAs: new roles in various cancers","volume":"12","author":"Rafiyan","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154330_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113574","article-title":"Lysophosphatidic acid (LPA) receptor modulators: structural features and recent development","volume":"222","author":"Meduri","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.154330_bib53","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1681\/ASN.2017010107","article-title":"Lysophosphatidic acid receptor antagonism protects against diabetic nephropathy in a Type 2 diabetic model","volume":"28","author":"Zhang","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbrc.2026.154330_bib54","doi-asserted-by":"crossref","first-page":"9643","DOI":"10.1073\/pnas.0600979103","article-title":"The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases","volume":"103","author":"Boucharaba","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.bbrc.2026.154330_bib55","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1194\/jlr.S091744","article-title":"Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential","volume":"60","author":"Tigyi","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbrc.2026.154330_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13064","article-title":"Lysophosphatidic acid receptor LPA3 prevents oxidative stress and cellular senescence in Hutchinson-Gilford progeria syndrome","volume":"19","author":"Chen","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.bbrc.2026.154330_bib57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1476-4598-9-140","article-title":"Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid","volume":"9","author":"Altman","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrc.2026.154330_bib58","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1158\/0008-5472.CAN-18-0498","article-title":"LPA4-mediated vascular network formation increases the efficacy of anti-PD-1 therapy against brain tumors","volume":"78","author":"Eino","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154330_bib59","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.bbrc.2018.08.026","article-title":"Lysophosphatidic acid receptor-2 (LPA2) and LPA5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells","volume":"503","author":"Takahashi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2026.154330_bib60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11010-017-2971-7","article-title":"Enhanced cellular functions through induction of LPA2 by cisplatin in fibrosarcoma HT1080 cells","volume":"431","author":"Takahashi","year":"2017","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbrc.2026.154330_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161825","article-title":"Higher LPA2 and LPA6 mRNA levels in hepatocellular carcinoma are associated with poorer differentiation, microvascular invasion and earlier recurrence with higher serum autotaxin levels","volume":"11","author":"Enooku","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2026.154330_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101133","article-title":"NAFLD nomenclature consensus group, a multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154330_bib63","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154330_bib64","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/liv.15695","article-title":"Exploring the landscape of steatotic liver disease in the general US population","volume":"43","author":"Ciardullo","year":"2023","journal-title":"Liver Int."},{"key":"10.1016\/j.bbrc.2026.154330_bib65","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/liv.15856","article-title":"Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults","volume":"44","author":"Song","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.bbrc.2026.154330_bib66","article-title":"Metabolic dysfunction-associated steatotic liver disease: current diagnostic pathways, noninvasive fibrosis assessment, and therapeutic strategies","volume":"18","author":"Bazan","year":"2026","journal-title":"Cureus"},{"key":"10.1016\/j.bbrc.2026.154330_bib67","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154330_bib68","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154330_bib69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12964-026-02997-8","article-title":"Liver sinusoidal endothelial cell fenestrations in metabolic liver disease: from molecular mechanisms to therapeutic perspectives","volume":"24","author":"Al-Mughalles","year":"2026","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.bbrc.2026.154330_bib70","doi-asserted-by":"crossref","DOI":"10.1007\/s10753-026-02545-z","article-title":"When the liver flares: inflammatory and immunometabolic mechanisms driving the transition from MASLD to MASH","author":"Vecchio","year":"2026","journal-title":"Inflammation"},{"key":"10.1016\/j.bbrc.2026.154330_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1087260","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"Rong","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbrc.2026.154330_bib72","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bbrc.2026.154330_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103910","article-title":"NAFLD and NASH: etiology, targets and emerging therapies","volume":"29","author":"Wei","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbrc.2026.154330_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70731","article-title":"Socioeconomic factors and their role in metabolic dysfunction-associated steatotic liver disease: a comprehensive review","volume":"46","author":"Wiering","year":"2026","journal-title":"Liver Int."},{"key":"10.1016\/j.bbrc.2026.154330_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415489","article-title":"Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment","volume":"23","author":"Guo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154330_bib76","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154330_bib77","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154330_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.bbrc.2026.154330_bib79","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5603\/ep.103993","article-title":"Association between adipose insulin resistance, serum lipoprotein(a) level, and MASLD in adult patients with T2DM in China","volume":"76","author":"Liu","year":"2025","journal-title":"Endokrynol. Pol."},{"key":"10.1016\/j.bbrc.2026.154330_bib80","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1007\/s00253-020-10614-y","article-title":"Crosstalk between ER stress, NLRP3 inflammasome, and inflammation","volume":"104","author":"Li","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154330_bib81","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1089\/ars.2010.3790","article-title":"Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease","volume":"15","author":"Gentile","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.bbrc.2026.154330_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2026.116222","article-title":"Bisphenol S induces hepatic steatosis and insulin resistance through AMPK inhibition and endoplasmic reticulum stress","volume":"215","author":"Sep\u00falveda-Fragoso","year":"2026","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bbrc.2026.154330_bib83","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000975","article-title":"Gut microbiota-derived indole-3-propionic acid alleviates endoplasmic reticulum stress by regulating FMO2 in MASLD","volume":"10","author":"Luo","year":"2026","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.bbrc.2026.154330_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2026.124419","article-title":"miR-302 protects the liver from glucolipotoxicity-induced lipid accumulation through activating AMPK and suppressing Elovl6 in HepG2 cells and also in mice","volume":"397","author":"Tsou","year":"2026","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2026.154330_bib85","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbrc.2026.154330_bib86","article-title":"ACSL1 aggravates thromboinflammation by LPC\/LPA metabolic axis in hyperlipidemia associated myocardial ischemia-reperfusion injury","volume":"12","author":"Jiang","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.bbrc.2026.154330_bib87","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1194\/jlr.M014985","article-title":"Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid","volume":"52","author":"Dusaulcy","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbrc.2026.154330_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262311425","article-title":"Role of ChREBP-PPAR\u03b1-FGF21 axis in metabolic dysfunction of MASLD","volume":"26","author":"Palacios Gir\u00f3n","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154330_bib89","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/ijms19041197","article-title":"PPAR agonists and metabolic syndrome: an established role?","volume":"19","author":"Botta","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154330_bib90","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbrc.2022.05.099","article-title":"Alcoholic fatty liver is blunted by rFGF21 administration in mice lacking adipose FGFR1: the role of FGF21 in PPAR\u03b1-mediated regulation of adipose tissue mass","volume":"619","author":"Xu","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2026.154330_bib91","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000480470","article-title":"Lysophosphatidic acid inhibits insulin signaling in primary rat hepatocytes via the LPA3 receptor subtype and is increased in obesity","volume":"43","author":"Fayyaz","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bbrc.2026.154330_bib92","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s00125-013-2891-3","article-title":"Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice","volume":"56","author":"Rancoule","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.bbrc.2026.154330_bib93","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/hep.28973","article-title":"Hepatocyte autotaxin expression promotes liver fibrosis and cancer","volume":"65","author":"Kaffe","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2026.154330_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101493","article-title":"Autotaxin signaling facilitates \u03b2 cell dedifferentiation and dysfunction induced by Sirtuin 3 deficiency","volume":"60","author":"Cao","year":"2022","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.bbrc.2026.154330_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208099","article-title":"Adipose-derived autotaxin regulates inflammation and steatosis associated with diet-induced obesity","volume":"14","author":"Brandon","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2026.154330_bib96","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1210\/me.2011-1229","article-title":"Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice","volume":"26","author":"Federico","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bbrc.2026.154330_bib97","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216333","article-title":"A type IV autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis","volume":"14","author":"Booijink","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbrc.2026.154330_bib98","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1021\/acschemneuro.2c00046","article-title":"Inhibition of autotaxin ameliorates LPA-mediated neuroinflammation and alleviates neurological dysfunction in acute hepatic encephalopathy","volume":"13","author":"Roy","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bbrc.2026.154330_bib99","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1021\/acsptsci.4c00066","article-title":"Effect of an autotaxin inhibitor, 2-(4-Chlorophenyl)-7-methyl-8-pentylimidazo[1,2-a] Pyrimidin-5(8H)-one (CBT-295), on bile duct ligation-induced chronic liver disease and associated hepatic encephalopathy in rats","volume":"7","author":"Roy","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bbrc.2026.154330_bib100","article-title":"Design and bioactivity evaluation of a novel autotaxin inhibitor with anti-hepatic fibrosis effects","volume":"15","author":"Liu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154330_bib101","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/aps.2010.135","article-title":"Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors","volume":"31","author":"Im","year":"2010","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26010946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26010946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:38:33Z","timestamp":1787071113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26010946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":101,"alternative-id":["S0006291X26010946"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154330","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of the LPC\/ATX\/LPA axis in metabolic dysfunction-associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154330"}}